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Abstract
Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resection and
sometimes adjuvant radiation. We report the case of a 71 year-old male patient undergoing carbon ion therapy for
extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remission at
6 weeks post completion of radiotherapy while RT-treatment itself was tolerated well with only mild side effects.
High dose radiation hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or
in cases when only a subtotal resection is planned or the resection is mutilating.
Introduction
Ameloblastic carcinomas are very rare odontogenic
tumors sometimes referred to as malignant ameloblas-
toma [1]. To date, 31 cases have been reported world-
wide, with the largest series describing 14 cases [2]
Definitions and classifications of ameloblastic carcino-
mas have changed over the years, there have been var-
ious classifications, the latest by Slootweg and Müller
[3] emphasizing histogenesis of the tumor leading to the
new WHO classification in 2005 [4]. Slootweg and Mül-
ler defined ameloblastic carcinoma as a tumor combin-
ing morphologic features of both ameloblastoma and
carcinoma, which can arise de novo, ex ameloblastoma,
or ex odontogenic cyst [3].
Most of the reported cases were discovered in the
mandible, only one fifth occur in the maxilla [5,6].
Though they claimed to exhibit a tendency towards
aggressive local growth and local relapse [1], distant
metastases are uncommon. Being a rare disease, there
are no treatment guidelines. However, standard treat-
ment has been complete surgical resection in reported
cases [5,7].
Report of a case
A 71-year-old patient with extensive relapse of an ame-
loblastic carcinoma was referred to our institution for
carbon ion therapy by his maxillo-facial surgeon. He
had been initially diagnosed 10 years ago when the
tumor was completely resected. Local recurrence was
found on a follow-up MRI scan 6 months prior to
presentation in our department with the patient com-
plaining of increasing pain in the left maxilla and probe
excision confirming the diagnosis of locally recurrent
ameloblastic carcinoma of the maxilla (Figures 1 and 2).
As the referring surgeon doubted successful removal of
the extensive tumor mass, faced with the inherent mor-
bidity, salvage surgery did not seem a feasible option.
Pre-therapeutic staging did not show signs of distant
spread and the patient was referred to radiotherapy.
Interdisciplinary discussion recommended high-dose
carbon ion therapy for this patient, hence he received a
dose of 60 GyE carbon ions.
Radiotherapy
Immobilization/planning examinations
Immobilization consisted of an individual thermoplastic
head mask with thermoplastic shoulder fixation. Plan-
ning examinations consisted of a planning CT scan
(3 mm slice thickness) with the patient positioned in the
individual fixation device and contrast-enhanced MRI
for 3 D image correlation.
Target volumes/dose prescription
CTV1 included the macroscopic tumor. PTV1 consisted
of a 3 mm margin around the CTV1 but did not extend
into critical organs at risk (i.e. brain stem, spinal cord).
CTV2 included CTV1 and all involved paranasal
sinuses. As there were no suspect lymph nodes, elective
nodal irradiation was not performed given the rarity of
nodal metastases.
We prescribed a dose of 44,8 GyE carbon ions in 2,99
GyE/fraction (5 fractions per week) to the CTV2,
followed by a boost to CTV1 with 14,9 GyE at 2,98
* Correspondence: alexandra.jensen@med.uni-heidelberg.de
1Dept of Radiation Oncology, INF 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
Jensen et al. Radiation Oncology 2011, 6:13
http://www.ro-journal.com/content/6/1/13
© 2011 Jensen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
GyE/fraction. aiming at covering the CTV with the 95%
prescription isodose. Figures 3, 4, and 5 show axial, cor-
onal, and sagittal views of the summation dose distribu-
tion (voxel-by-voxel addition of basic and boost plan)
with 100% corresponding to 60.0 GyE. Figure 6 depicts
the dose-volume-histogram (DVH). Treatment was
given at the HIT (Heidelberg Ion-Beam Therapy Centre)
after inverse treatment planning in active beam applica-
tion (raster-scanning method) [8]. A monoenergetic
carbon ion beam with a full-width/half-maximum
(FWHM) of 5 mm is extracted from the accelerator sys-
tem (synchrotron) and magnetically deflected to subse-
quently scan all planned iso-energetic slices roughly
corresponding to the tumour’s radiological depth. Using
this method almost any desired dose distribution can be
Figure 1 Extensive ameloblastic carcinoma originating from
the left maxilla: axial, contrast-enhanced T1 weighted MRI.
Figure 2 Extensive ameloblastic carcinoma originating from
the left maxilla: coronal, contrast-enhanced T1 weighted MRI.
Figure 3 Carbon ion dose distribution: (summation: primary
plan to 45 GyE C12, boost plan to 15 GyE) 100%
corresponding to 60 GyE, axial view. Orange outline: CTV2; red
outline: CTV 1; Green star: local maximum dose within the slice. Red
star: global maximum.
Figure 4 Carbon ion dose distribution: (summation: primary
plan to 45 GyE C12, boost plan to 15 GyE) 100%
corresponding to 60 GyE, coronal view. Orange outline: CTV2; red
outline: CTV 1; Green star: local maximum dose within the slice. Red
star: global maximum.
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created and dose to surrounding critical structures can
be minimized.
Daily image guidance consisted of orthogonal x-ray
controls in treatment position with the x-ray tube/
receptor mounted on a robot to allow imaging in almost
any treatment table position. After acquisition of ortho-
gonal x-rays, an automatic 2D-3 D pre-match was car-
ried out (Siemens syngo PT treatment) and verified by
the radiotherapist/radiation oncologist with regard to
bony anatomy. Manual adjustment of the match was
carried out on-line and the resulting correction vector,
including rotations, subsequently applied to the patient
position. Patient position was controlled in each session
and shifts were always corrected using a robotic table
allowing position correction in six degrees of freedom.
Treatment schedule/follow-up
Treatment was carried out in 5 fractions per week hence
over approximately 4 weeks.
The first follow-up examination including clinical
examination and diagnostic, contrast-enhanced MRI was
carried out 6 weeks post completion of radiation treat-
ment, the second follow-up 3 months thereafter. Further
follow-up radiooncological follow-up appointments are
scheduled in 6-monthly intervals. The patient was also
encouraged to undergo regular check-ups including full
ENT clinical examinations in regular intervals (usually
every 6 weeks).
Treatment outcome
Treatment was tolerated well. Only very mild skin
changes (hyperpigmentation CTC°I and erythema CTC°
I, no desquamation) over the left cheek and mild
mucous membrane reactions (mucositic CTC °I-II) at
the soft/hard left palate could be observed. No change
of taste, dysphagia, or weight loss was observed. There
was only a very mild xerostomia (CTC°I). When the
patient presented to our department again 6 weeks post
completion of radiotherapy, he was in a very good clini-
cal state, the pain in the right maxilla was already resol-
ving steadily. While the patient was on oral morphin
sulfates during treatment, only needed non-steroidal
anti-inflammatories occasionally on follow-up. No resi-
dual acute radiogenic reactions could be detected other
than residual xerostomia (CTC°I). Furthermore, no resi-
dual tumor could be detected on his follow-up MRI-
scans 6 weeks post completion of therapy (Figures 7 and
8) and 3 months thereafter.
Discussion
With the disease being extremely rare, clinicians have to
rely on various reported cases for guidance. Hence, the
establishment of treatment standards is not possible.
Radiotherapy has been controversially discussed in the
past. Most reported cases underwent surgical removal.
Reports of ameloblastic carcinomas receiving radiation
therapy are scarce and mostly from the pre-3 D and
cobalt era [9-11]. To our knowledge, radiotherapy has
only been given as adjuvant therapy in only a few cases
[11-15] within the past 20 years. Radiation doses
between 41,4 Gy and 54 Gy have been comparatively
conservative [12,13,16] or not been reported [2,14,17]
leading to local relapse in half of the cases. Higher
radiation doses between 66 and 72 Gy in close margin/
positive-margin resections as reported by Philip et al
[15] lead to local control for the duration of available
follow-up (0.8 - 3.3 years) in the reported 3 cases.
Figure 5 Carbon ion dose distribution: (summation: primary
plan to 45 GyE C12, boost plan to 15 GyE) 100%
corresponding to 60 GyE, sagittal view. Orange outline: CTV2; red
outline: CTV 1; Green star: local maximum dose within the slice. Red
star: global maximum.
Figure 6 Carbon ion summation plan: DVH.
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While it has been discussed in cases with incomplete
resections or nodal metastases, there is no evidence for
radiotherapy as a potentially definitive treatment modal-
ity yet. Faced with the opinion that aggressive treatment
(recommending surgical wide excision with 2-3 cm
margins [1]) is warranted to counterbalance high ten-
dency of local relapse, RT was given in a high-precision
technique as carbon ion therapy. Carbon ion therapy in
active beam application with raster-scanned particle
beams is able to produce extremely steep gradients
hence delivering high doses to the tumor while sparing
normal surrounding tissues. In contrast to intensity-
modulated radiation therapy, integral dose to the irra-
diated volume is substantially lower. Also, increased bio-
logical effectiveness of carbon ion beams has been
shown to be beneficial in other radioresistant tumors
[18-20].
While it is beyond the scope of this case report to
establish a clinical standard, our case shows that fast
complete remissions of extensive ameloblastic carcino-
mas are possible using carbon ion therapy at substantial
doses. Moreover, this treatment is accompanied by very
mild treatment-related side effects (erythema, xerosto-
mia CTC°I and mucositis CTC °I-II) and no major
radiation-related toxicity; hence the patient could be
spared extensive, mutilating and potentially incomplete
surgical procedures.
To our knowledge, this is the first case of ameloblastic
carcinoma being treated with carbon ion therapy and
resulted so far in an excellent posttherapeutic outcome.
Therefore radiotherapy with carbon ions should be con-
sidered in the definitive treatment of these rare tumors.
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